Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
GENOCEA BIOSCIENCES, INC. (GNCA) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/04/2021 8-K Quarterly results
11/18/2020 8-K Investor presentation
Docs: "0 3 6 8 10 12 14 16 18 20 22 24"
11/09/2020 8-K Investor presentation
Docs: "GEN-009 Part B SITC"
07/30/2020 8-K Quarterly results
07/06/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
01/13/2020 8-K Investor presentation
Docs: "Management presentation issued by Genocea Biosciences, Inc. on January 13, 2020"
11/19/2019 8-K Quarterly results
01/07/2019 8-K Investor presentation
Docs: "Genocea Investor Presentation, January 2019"
06/08/2018 8-K Investor presentation
Docs: "Management Presentation issued by Genocea Biosciences, Inc. on June 8, 2018"
09/27/2017 8-K Quarterly results
07/24/2017 8-K Form 8-K - Current report:
01/05/2017 8-K Form 8-K - Current report
09/29/2016 8-K Investor presentation
Docs: "CAMBRIDGE, Mass., September 29, 2016",
"Investor Presentation"
03/31/2016 8-K Investor presentation
Docs: "Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing",
"Positive 12 Month Efficacy Results GEN-003 Immunotherapy for Genital Herpes Phase 2 Dose Optimization Study 31 March 2015 Exhibit 99.2"
01/11/2016 8-K Investor presentation
Docs: "Management Presentation issued by Genocea Biosciences, Inc. on January 11, 2016"
11/05/2015 8-K Investor presentation, Quarterly results
Docs: "Genocea Reports Third Quarter 2015 Financial Results - Company Reports Recent Milestones and Announces Expansion of ATLAS TM Technology into Immuno-Oncology - - Conference Call and Webcast Scheduled for 9:00 a.m. ET Today -",
"Management Presentation issued by Genocea Biosciences, Inc. on November 5, 2015"
10/07/2015 8-K Investor presentation
Docs: "Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003 - Sustained viral shedding rate reduction of 58 percent from baseline at best dose improves upon established attractive product profile - - Efficacy seen consistently across several potential Phase 3 clinical endpoints - - End of Phase 2 meeting with FDA expected in late 2016 - - Company to host conference call at 9 a.m. ET today; data to be presented at IDWeek 2015 -",
"Positive 6 Month Durability Results GEN-003 Immunotherapy for Genital Herpes Phase 2 Dose Optimization Study 7 October 2015 Exhibit 99.2 Safe Harbor Statement This"
05/20/2015 8-K Investor presentation
Docs: "Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003 - Highly statistically significant 55 percent reduction in viral shedding rate with best dose - - Company to host conference call at 9 a.m. EDT today including guest speaker Peter A. Leone, MD -",
"Investor Presentation"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy